NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

LRMR

Larimar Therapeutics Inc

Jul 03 • 04:00PM ET

3.20

Dollar change +0.09
Percentage change 2.89	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BMRN FOLD QURE RPTX ARWR ONCT SRPT CRSP RIGL

| Held by: IWM VTI IWN VXF IBB VTWO IWC AVSC VTWG RSSL

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.49	Insider Own	43.06%	Shs Outstand	64.03M	Perf Week	3.90%
Market Cap	204.89M	Forward P/E	-	EPS next Y	-1.92	Insider Trans	0.00%	Shs Float	36.46M	Perf Month	32.78%
Enterprise Value	52.23M	PEG	-	EPS next Q	-0.48	Inst Own	62.12%	Short Float	17.81%	Perf Quarter	45.45%
Income	-95.23M	P/S	-	EPS this Y	-45.50%	Inst Trans	-0.42%	Short Ratio	5.08	Perf Half Y	-18.16%
Sales	0.00M	P/B	1.42	EPS next Y	0.28%	ROA	-45.52%	Short Interest	6.49M	Perf YTD	-17.31%
Book/sh	2.25	P/C	1.30	EPS next 5Y	-7.80%	ROE	-50.77%	52W High	11.20 -71.43%	Perf Year	-61.17%
Cash/sh	2.46	P/FCF	-	EPS past 3/5Y	23.60% 50.78%	ROIC	-64.33%	52W Low	1.61 98.76%	Perf 3Y	52.38%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.96% 11.35%	Perf 5Y	-75.38%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-54.29%	Oper. Margin	-	ATR (14)	0.29	Perf 10Y	-99.26%
Dividend Ex-Date	-	Quick Ratio	7.48	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	62.03	Recom	1.09
Dividend Gr. 3/5Y	- -	Current Ratio	7.48	EPS Q/Q	-67.32%	SMA20	11.58%	Beta	0.92	Target Price	20.80
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	29.42%	Rel Volume	0.40	Prev Close	3.11
Employees	65	LT Debt/Eq	0.03	Earnings	Apr 30 BMO	SMA200	-23.63%	Avg Volume	1.28M	Price	3.20
IPO	Jun 19, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	-9.97% -	Trades		Volume	516,014	Change	2.89%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-29-25	Initiated	Truist	Buy	$18
Oct-16-24	Initiated	Oppenheimer	Outperform	$26
Oct-03-24	Initiated	Wedbush	Outperform	$22
Oct-02-24	Initiated	H.C. Wainwright	Buy	$15
Sep-04-24	Initiated	Robert W. Baird	Outperform	$16
Apr-03-24	Initiated	Leerink Partners	Outperform	$25
Nov-17-23	Upgrade	Citigroup	Neutral → Buy	$4.50
Oct-19-22	Initiated	Guggenheim	Buy	$12
Feb-15-22	Downgrade	William Blair	Outperform → Mkt Perform
Feb-10-21	Initiated	JMP Securities	Mkt Outperform
Feb-01-21	Initiated	William Blair	Outperform	$29

Show Previous Ratings

Jun-23-25 07:00AM	Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia Program (GlobeNewswire) -6.56%
Jun-20-25 04:05PM	Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia (GlobeNewswire) -5.47%
May-21-25 11:22AM	Larimar Therapeutics, Inc.'s (LRMR): Analysts See 957% Upside Potential (Insider Monkey) -6.31%
Apr-30-25 07:00AM	Larimar Therapeutics Reports First Quarter 2025 Financial Results (GlobeNewswire) +10.88%
Apr-04-25 01:12PM	Larimar Therapeutics: Initiating Hold Rating With Upcoming Catalysts (Seeking Alpha)
07:00AM	Loading…
Mar-24-25 07:00AM	Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire) -10.24%
Mar-03-25 04:05PM	Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference (GlobeNewswire) -12.54% +5.28%
Jan-23-25 04:05PM	Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia (GlobeNewswire)
Dec-17-24 07:20AM	Larimar Therapeutics announces initial data from OLE study of nomlabofusp (TipRanks) -10.56%
Dec-16-24 07:00AM	Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study and Progress Across Nomlabofusp Program for Friedreich's Ataxia (GlobeNewswire) -21.72%
07:00AM	Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreichs Ataxia (GlobeNewswire)
Nov-18-24 07:00AM	Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024 (GlobeNewswire) -7.92%
Oct-30-24 07:00AM	Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results (GlobeNewswire) +8.74%
Sep-19-24 07:00AM	Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research (GlobeNewswire)
Aug-27-24 08:00AM	Larimar Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
07:00AM	Loading…
Aug-07-24 07:00AM	Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results (GlobeNewswire) -6.54%
May-30-24 04:05PM	Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia (GlobeNewswire) +12.68%
May-22-24 11:25AM	Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study (Zacks)
May-21-24 07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) +8.53%
May-20-24 04:05PM	Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia (GlobeNewswire)
May-09-24 01:55PM	LRMR Stock Earnings: Larimar Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
07:00AM	Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results (GlobeNewswire)
Mar-20-24 01:32PM	Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks (Insider Monkey)
Mar-14-24 09:53PM	LRMR Stock Earnings: Larimar Therapeutics Misses EPS for Q4 2023 (InvestorPlace) -6.51%
05:32PM	Larimar Therapeutics Inc (LRMR) Reports Full Year and Q4 2023 Financial Results (GuruFocus.com)
04:05PM	Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development (GlobeNewswire)
Mar-11-24 04:05PM	Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's Ataxia (GlobeNewswire) -15.39%
Mar-06-24 04:05PM	Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-20-24 01:47PM	Hedge Fund and Insider Trading News: Bill Ackman, George Soros, Arkhouse Management, TYR Capital, Borea Asset Management, Larimar Therapeutics, Inc. (LRMR), and More (Insider Monkey) -5.63%
Feb-19-24 01:48PM	Hedge Fund and Insider Trading News: Bill Ackman, David Tepper, Mark Yusko, Elliott Management, Conestoga Capital Advisors, Larimar Therapeutics Inc (LRMR), Agree Realty Corporation (ADC), and More (Insider Monkey)
04:20PM	Loading…
Feb-16-24 04:20PM	Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -5.63%
Feb-14-24 06:15AM	Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock (GlobeNewswire) +36.84%
Feb-13-24 04:18PM	Larimar Therapeutics Announces Proposed Underwritten Public Offering (GlobeNewswire) +11.62%
Feb-12-24 07:00AM	Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia (GlobeNewswire)
Nov-14-23 07:00AM	Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results (GlobeNewswire) +7.11%
Nov-01-23 04:05PM	Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference (GlobeNewswire)
Oct-03-23 04:05PM	Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors (GlobeNewswire) -5.83%
Aug-31-23 04:05PM	Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference (GlobeNewswire)
Aug-10-23 07:00AM	Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results (GlobeNewswire)
Aug-07-23 09:22AM	Larimar Therapeutics Insiders Placed Bullish Bets Worth US$1.2m (Simply Wall St.) -7.19%
Jul-25-23 09:59AM	These 2 Strong Buy Penny Stocks Could Go Boom, Say Analysts (TipRanks) +7.67%
07:00AM	Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601s Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial (GlobeNewswire)
Jul-17-23 04:05PM	Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer (GlobeNewswire)
Jun-21-23 04:05PM	Larimar Therapeutics Set to Join Russell 3000® Index (GlobeNewswire)
May-15-23 07:00AM	Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trials 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreichs Ataxia and First Quarter 2023 Financial Results (GlobeNewswire) -29.05%
Mar-28-23 04:05PM	Larimar Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Days (GlobeNewswire)
Mar-14-23 07:00AM	Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results (GlobeNewswire)
Feb-07-23 04:05PM	Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer (GlobeNewswire) +6.52% +7.99%
Nov-21-22 04:05PM	Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-10-22 07:00AM	Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results (GlobeNewswire)
Nov-07-22 04:05PM	Larimar Therapeutics to Participate in the Guggenheim 4th Annual Immunology & Neurology Day (GlobeNewswire)
Oct-20-22 08:00AM	Larimar Therapeutics Announces Issuance of U.S. Patent Providing Composition of Matter Protection for CTI-1601 (GlobeNewswire)
Oct-19-22 04:05PM	Larimar Therapeutics Announces Oral and Poster Presentations at the Upcoming International Congress for Ataxia Research (GlobeNewswire)
Sep-16-22 01:00PM	Larimar Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Option to Purchase Additional Shares (GlobeNewswire) -5.04%
Sep-14-22 07:04AM	Larimar Therapeutics Announces $70 Million Underwritten Offering (GlobeNewswire) +15.56%
07:01AM	Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreichs Ataxia Patients (GlobeNewswire)
Aug-11-22 04:05PM	Larimar Therapeutics Provides Updates on CTI-1601 Clinical Program Following a Type C Meeting with the U.S. Food and Drug Administration and Reports Second Quarter 2022 Operating and Financial Results (GlobeNewswire) +7.07%
Jul-28-22 04:05PM	Larimar Therapeutics Announces Presentation at the Upcoming Gordon Research Conference on Neurobiology of Brain Disorders (GlobeNewswire)
Jun-28-22 08:00AM	Larimar Therapeutics Announces Oral Presentation at the Upcoming Gordon Research Conference on Mitochondria and Chloroplasts (GlobeNewswire)
06:05AM	We're Keeping An Eye On Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Rate (Simply Wall St.)
Jun-02-22 08:00AM	Larimar Therapeutics Announces Upcoming Scientific Conference Presentations (GlobeNewswire)
May-19-22 08:00AM	Larimar Therapeutics Announces Upcoming Poster Presentations at the 4th Pan American Parkinsons Disease and Movement Disorders Congress (GlobeNewswire)
May-12-22 07:00AM	Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results (GlobeNewswire) -7.91%
Apr-29-22 06:27AM	Despite recent gains, Larimar Therapeutics, Inc. (NASDAQ:LRMR) insiders are still down US$273k after purchasing last year (Simply Wall St.) -5.84%
Apr-13-22 10:40AM	Down 21.2% in 4 Weeks, Here's Why You Should You Buy the Dip in Larimar (LRMR) (Zacks)
Mar-25-22 07:00AM	Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results (GlobeNewswire)
Feb-16-22 11:57AM	Larimar Therapeutics' stock plunges on FDA decision; could implement cost-cutting measures (American City Business Journals)
Feb-14-22 04:01PM	Larimar Therapeutics Provides Update on CTI-1601 Clinical Program (GlobeNewswire) -52.09%
Jan-19-22 06:53AM	Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Nov-22-21 07:00AM	Larimar Therapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference (GlobeNewswire)
Nov-20-21 08:40AM	In spite of Larimar Therapeutics, Inc.'s recent pullback, insiders still gained about US$85k after buying earlier this year. (Simply Wall St.)
Nov-15-21 07:00AM	Larimar Therapeutics to Participate in the Guggenheim Virtual Neuro/Immunology Conference (GlobeNewswire)
Nov-12-21 07:00AM	Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results (GlobeNewswire) -8.72%
Sep-16-21 08:00AM	Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event (GlobeNewswire) -7.48%
Sep-02-21 04:01PM	Larimar Therapeutics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference (GlobeNewswire) +5.81%
Aug-22-21 10:12AM	What You Need To Know About Larimar Therapeutics, Inc.'s (NASDAQ:LRMR) Investor Composition (Simply Wall St.)
Aug-19-21 07:00AM	Larimar Therapeutics Announces Upcoming Oral Presentation at the World Orphan Drug Congress (GlobeNewswire)
Aug-12-21 07:00AM	Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results (GlobeNewswire) +17.79%
Aug-09-21 08:48AM	Why Larimar (LRMR) Might Surprise This Earnings Season (Zacks)
Jul-23-21 12:00PM	Larimar (LRMR) Upgraded to Buy: Here's Why (Zacks)
Jul-08-21 04:01PM	Larimar Therapeutics to Present at the William Blair Biotech Focus Conference 2021 (GlobeNewswire)
Jun-11-21 07:00AM	Larimar Therapeutics to Present at the JMP Securities Life Sciences Conference (GlobeNewswire)
Jun-05-21 07:55PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR (Newsfile)
Jun-02-21 10:56PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR (GlobeNewswire)
Jun-01-21 04:55AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR (PR Newswire)
May-29-21 10:59PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR (Newsfile)
May-25-21 05:41PM	Larimar Therapeutics Reports FDA Clinical Hold on CTI-1601 and Termination of Recently Announced Private Placement Financing (GlobeNewswire) -10.59% -33.46%
May-21-21 09:18AM	Larimar Therapeutics Announces $95 Million Private Placement Financing (GlobeNewswire) +11.17%
May-20-21 04:31PM	Larimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreichs Ataxia (GlobeNewswire) +10.17%
May-11-21 07:00AM	Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreichs Ataxia (GlobeNewswire) -36.28%
May-10-21 04:05PM	Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results (GlobeNewswire) -5.34%
Mar-04-21 07:00AM	Larimar Therapeutics Reports Fourth Quarter and Full Year 2020 Operating and Financial Results (GlobeNewswire)
Mar-01-21 03:54AM	Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation (Simply Wall St.)
Feb-18-21 04:01PM	Larimar Therapeutics to Present at the SVB Leerink 10th Annual Global Healthcare Conference (GlobeNewswire) +6.38%
Dec-16-20 07:23PM	Is LRMR A Good Stock To Buy Now? (Insider Monkey)
Dec-15-20 08:00AM	Larimar Therapeutics Added to NASDAQ Biotechnology Index (GlobeNewswire)
Dec-08-20 07:30AM	Larimar Therapeutics Announces Completion of Dosing of the Single Ascending Dose Clinical Trial in Friedreichs Ataxia Patients and Provides Program Update (GlobeNewswire)
Nov-13-20 08:00AM	Larimar Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +16.58%
Nov-10-20 08:00AM	Larimar Therapeutics Reports Third Quarter 2020 Operating and Financial Results (GlobeNewswire) -6.12%
Oct-14-20 10:18PM	Hedge Funds Are Betting On Larimar Therapeutics, Inc. (LRMR) (Insider Monkey)

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LRMR

Larimar Therapeutics Inc

Upgrade your FINVIZ experience